Group 1 - The company, Giant Bio (02367), announced a placement and subscription agreement on April 16, 2025, where the seller agreed to sell 35 million shares at a price of HKD 66.65 per share [1] - The placement price of HKD 66.65 represents a discount of approximately 9.50% compared to the closing price of HKD 73.65 on April 16, 2025 [1] - The total amount expected from the placement and subscription is approximately HKD 2.333 billion, with a net amount of about HKD 2.294 billion after deducting commissions and estimated expenses [1] Group 2 - The net proceeds from the placement and subscription are intended for core business development and ecosystem layout, including brand promotion, marketing, category expansion, overseas business, R&D investment, and general corporate purposes [1] - The announcement states that the fundraising will enhance the company's financial strength, market competitiveness, and overall capabilities, promoting long-term healthy and sustainable development [1] - The placement is expected to attract high-quality institutional investors, enriching the company's shareholder base and improving share liquidity [1] Group 3 - The seller is a limited liability company registered under the laws of the British Virgin Islands, holding approximately 56.10% of the company's existing issued share capital [2] - The seller acts as a holding vehicle for the FY Family Trust, with the spouse of executive director Yan Jianya serving as the trustee and beneficiary [2]
巨子生物拟折让约9.50%先旧后新配股 最高净筹约22.94亿港元